Pedestrians walk past Biogen Inc. headquarters in Cambridge, Mass.(Adam Glanzman/Bloomberg)The makers of a highly anticipated experimental Alzheimer's drug said Tuesday that the medicine moderately slows cognitive decline, but that more study was needed to establish its safety.The details provided by Tokyo-based Eisai Co. and Cambridge, Mass.-based Biogen Inc., have been the subject of intense anticipation by doctors and Wall Street since they announced in September that the drug, lecanemab, had slowed cognitive decline by 27 percent compared to a placebo.
#researchers #expectations #controversy #effectiveness #complications #pedestrians #wall-street #blood-clots #multibillion
[
add
]
[
|
|
...
]